The billionaire was panned for overspending on Twitter, but the platform is winning him favor with Donald Trump and ...

Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after ...

Key Takeaways Wedbush upgraded Snowflake as the analysts predicted that the artificial intelligence software era is ...

Major technology stocks are positioned for a strong year-end rally as artificial intelligence initiatives accelerate and ...

Investing.com -- Wedbush analysts expect tech stocks to end the year on a positive note with a “Santa rally,” citing positive catalysts including deregulation under Donald Trump’s second term and ...

Wedbush notes that in the past two weeks Kioxia filed for an IPO and SanDisk released its 10-12B, telling investors that data from these ...

Wedbush has assumed coverage of Voyager Therapeutics (NASDAQ:VYGR) with an outperform rating, highlighting the company’s TRACER platform. The investment firm said it believes TRACER alone should ...

The EV maker’s stock gained 3.7% on Friday, leaving the shares ahead nearly 40% for the year and giving it a market value of ...

A potential Trump administration may ease regulations for self-driving vehicles, accelerating Tesla's progress ...

Tesla’s strategic pivot toward AI and autonomy reinforces its position as a leading disruptive technology company, not merely an automaker, the analysts said. Investors are closely watching regulatory ...

Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after assuming coverage of the name. The firm added the company’s tau antibody for ...